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Abstract 
Background: To evaluate plasma chaperonin containing TCP1 complex subunit 3 (CCT3) and IQ‑motif‑containing 
GTPase‑activating protein‑3 (IQGAP3) as biomarker for hepatocellular carcinoma (HCC) screening and diagnosis.
Methods: Blood samples were collected from 126 HCC patients with HCC, 88 patients with cirrhosis and 50 healthy 
volunteers to detect plasma α‑fetoprotein (AFP), CCT3 and IQGAP3 levels. Plasma AFP, CCT3 and IQGAP3 protein levels 
were measured by enzyme linked immunosorbent assay (ELISA).
Results: In the plasma of HCC patients, both CCT3 and IQGAP3 were significantly higher than in patients with cir‑
rhosis and in healthy controls (P < 0.01). CCT3 and IQGAP3 protein level correlated well with HCC etiology, tumor 
size, TNM stage, and child‑pugh classification. CCT3 protein had higher sensitivity in the diagnosis of HCC when 
compared with AFP (87.3 vs 69.8 %). In addition, CCT3 and IQGAP3 protein were able to complement AFP in detect‑
ing AFP‑negative HCC patients with sensitivity and specificity of 92.1 and 70.5 % and 81.6 and 71.6 %, respectively. In 
the small HCC group, CCT3 and IQGAP3 protein had sensitivity of 76.6 and 74.5 %, respectively. The combination of 
AFP + CCT3 + IQGAP3 (0.954) had significantly superior discriminative ability than AFP alone (0.815; P < 0.01).
Conclusions: CCT3 and IQGAP3 are novel complementary biomarkers for HCC screening and diagnosis, especially 
for AFP‑negative and small HCC patients.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in the world and the third leading cause of 
cancer-related mortality, causing 696,000 deaths each 
year [1]. Although the prognosis of late-stage HCC has 
improved during the past two decades, its 5-year survival 
rate is still low [2].
The most effective therapy for HCC is surgical resec-
tion, but tumors at later stages may be inoperable. Tra-
ditional detection methods such as ultrasound, magnetic 
resonance imaging and computed tomography are help-
ful and efficient in detecting tumor location and metasta-
sis, but cannot reliably detect early-stage HCC, and fail to 
diagnose HCC when they are used alone [3, 4]. To date, 
α-fetoprotein (AFP) is the most important serological 
marker recommended for screening patients at high-risk 
for HCC. However, nearly 40  % of patients with HCC, 
including some with small tumors, have normal serologi-
cal AFP levels [5]. Therefore, it is important to develop 
reliable biomarkers for early detection and diagnosis of 
HCC for clinical treatment and prognosis.
The chaperonin containing TCP1 complex (CCT), also 
called TRiC or c-cpn, mediates protein folding in the 
cytosol. Chaperonins are ATP-dependent protein-folding 
machines that are present in all kingdoms of life. They 
consist of two back-to-back stacked oligomeric rings 
with a cavity at each end, where protein substrate bind-
ing and folding take place [6, 7]. The chaperonin family 
includes mitochondrial heat shock protein 60, bacterial 
GroEL, plastid Rubisco subunit-binding protein, and 
archaea group II chaperonins [8, 9]. CCT3 (60 kDa) is a 
critical subunit in CCT/TRiC complexes, which plays a 
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significant role in specifically binding these factors dur-
ing protein folding or refolding. Several studies have 
shown by quantitative RT-PCR and western blotting that 
CCT3 is overexpressed in patients with HCC [10–14]. 
CCT3 can affect the progression of HCC, by having an 
impact on the transport of phosphorylated signal trans-
ducer and activator of transcription (STAT)3/STAT3 into 
the nuclei of HCC cells. CCT3 may play a role in regu-
lating microtubular structure and function (capture of 
kinetochores) and affect the cellular sensitivity to these 
microtubule-targeting agents. However, the role as a bio-
marker in HCC and other cancer has not been evaluated.
The IQ-motif-containing GTPase-activating protein 
(IQGAP) family comprises three members: IQGAP1, 
IQGAP2 and IQGAP3. IQGAP3 is the latest addition to 
this family. It was involved in the proliferation of epithe-
lial cells, however, its role in tumorigenesis remains to 
be determined [15, 16]. IQGAP3 promotes cell prolifera-
tion through the Ras/extracellular signal-regulated kinase 
(ERK) pathway [17]. Expression of IQGAP3 was increased 
during proliferation at sites of cell–cell contact in hepato-
cytes. Therefore, one of the most important future issues 
is to identify the cell-density-sensing units at cell–cell 
contacts in association with IQGAP3. The IQGAP3-
related signaling pathway may be one of the complex 
signaling routes involved in liver regeneration. The contri-
bution of Ras-, Rac-, and Cdc42-binding IQGAP3 to liver 
regeneration suggests that IQGAP3 might lead to effec-
tive coordination of these signaling processes for cell pro-
liferation and tissue remodeling [18].
Skawran et  al. [13] found that CCT3 and IQGAP3 
genes are all localized on 1q22 and they are up-regulated 
at the gene level in HCC. To date, it is not clear if CCT3 
and IQGAP3 can be detected at the plasma level, nor is 
the relationship known between plasma AFP, CCT3 and 
IQGAP3 levels in different stages of HCC. In this study, 
we investigated CCT3 and IQGAP3 at plasma levels in 
patients with HCC or cirrhosis and in healthy individu-
als, and evaluated their application in detecting small and 
AFP-negative tumors in patients with HCC. Our results 
demonstrate that CCT3 and IQGAP3 are novel biomark-
ers complementary to AFP in HCC diagnosis, whose 
expression is probably independent of AFP. This is espe-
cially valuable when AFP is negative and HCC is at an 
early stage. Thus, determination of CCT3 and IQGAP3 in 
combination with AFP increases the diagnostic sensitiv-
ity and specificity of HCC.
Methods
Patient information
We enrolled 126 HCC patients, 88 patients with cirrho-
sis, and 50 healthy individuals from People’s Hospital 
of Zhengzhou University (Henan, China) between May 
2014 and September 2015. Patients were evaluated and 
diagnosed by physical examination, laboratory tests, 
ultrasonography, computed tomography or magnetic 
resonance imaging. In patients who underwent surgery, 
HCC was confirmed by pathological examination. No 
patients received preoperative radiotherapy or chemo-
therapy and none of the cancer patients had other types 
of malignancy. HCC was staged according to the child-
pugh and tumor-node-metastasis (TNM) classifications 
[19]. Details about the patients with HCC or cirrhosis are 
listed in Tables 1 and 2. The Hospital Ethics Committee 
approved this study. All participants were fully informed 
and gave written informed consent.
Blood sampling
Peripheral blood samples (3–5  mL) from each patient 
were collected in anti-coagulated tubes containing ethyl-
ene diamine tetraacetie acid (EDTA). All blood samples 
from patients with HCC were collected before surgery. 
The samples from healthy donors were obtained from the 
Hospital Physical Examination Center. Samples were cen-
trifuged at 1000×g for 15 min at room temperature, and 
stored at −80 °C until testing.
Measurement of plasma AFP, CCT3 and IQGAP3 protein 
levels
Plasma CCT3 and IQGAP3 (sensitivity, 5.0 pg/mL; assay 
range 31.2–1000  pg/mL) levels were measured using a 
commercially available ELISA kit (Novatein Biosciences, 
Woburn, MA, USA). Plasma AFP levels were detected 
using an ELISA kit (R&D Systems, Minneapolis, MN, 
USA) (sensitivity, 0.046  ng/mL; assay range 0.312–
20.0  ng/mL). Ten microliters of plasma samples were 
mixed with 40 μL of sample dilution buffer and incubated 
in 96-well plates coated with antibodies for 30  min at 
37 °C. The solutions were decanted followed by washing. 
Fifty-microliter horseradish-peroxidase-conjugated sec-
ondary antibodies were added to the wells and incubated 
for 30  min. After washing, 50  μL of each chromogen 
solution A and chromogen solution B were added to the 
wells, and incubated for 15 min at 37 °C. The reaction was 
stopped by adding 50  μL stop solution. The OD values 
were determined in a 96-well plate reader (Bio-Rad Labo-
ratories, Hercules, MA, USA) at 450  nm. All tests were 
performed in duplicate. Average OD values were calcu-
lated and the plasma levels of CCT3, IQGAP3 and AFP 
proteins were determined by standard curve. Data were 
collected and analyzed, intra-batch variation was con-
trolled within 5 %, and inter-batch variation was <10 %.
Statistical analysis
All data are summarized and expressed as the mean ± SD. 
The Mann–Whitney U test or Kruskal–Wallis test was 
Page 3 of 8Qian et al. Cancer Cell Int  (2016) 16:55 
Table 1 Clinical characteristics of patients with HCC
HBV hepatics B virus, HCV hepatics C virus, HCC hepatocellular carcinoma, SD standard deviation, TNM tumor-node-metastasis
a By Mann–Whitney U test
b By Kruskal–Wallis test
Parameters Patients, n (%) CCT3 P value IQGAP3 P value
x ± SD, pg/mL x ± SD, pg/mL
Age (years)
 ≤55 38 (30.2) 285.53 ± 203.38 0.106a 217.79 ± 163.06 0.043a
 >55 88 (69.8) 350.6 ± 207.33 287.83 ± 181.55
Gender
 Male 84 (66.7) 354.67 ± 217.39 0.08a 270.35 ± 167.19 0.748a
 Female 42 (33.3) 283.6 ± 199.51 259.43 ± 201.11
Etiology
 HBV(+) 72 (57.1) 284.79 ± 195.82 0.019b 218.82 ± 177.52 0.002b
 HCV(+) 31 (24.6) 407.16 ± 209.483 342.32 ± 150.01
 Other 23 (18.3) 72.87 ± 209.96 314.70 ± 74.99
Tumor diameter (cm)
 ≤2 47 (37.3) 279.13 ± 217.01 0.011b 212.74 ± 170.72 0.025b
 >2 and ≤5 25 (19.8) 432.92 ± 155.60 327.80 ± 138.07
 >5 54 (42.9) 328.91 ± 205.99 285.39 ± 191.04
Number of lesions
 ≤2 61 (48.4) 272.52 ± 200.87 0.002a 230.36 ± 166.22 0.026a
 >2 65 (51.6) 385.83 ± 199.91 300.82 ± 184.04
Extra‑hepatic metastasis
 Yes 34 (27.0) 407.00 ± 215.60 0.014a 334.03 ± 207.84 0.27a
 No 92 (73.0) 302.88 ± 198.33 241.83 ± 160.53
Differentiation degree
 Well 47 (37.3) 316.21 ± 208.54 0.245b 252.85 ± 154.02 0.133b
 Moderate 43 (34.1) 308.37 ± 201.41 235.53 ± 178.15
 Poor 36 (28.6) 377.25 ± 211.73 322.03 ± 199.74
TNM stage
 I + II 71 (56.3) 282.56 ± 199.01 0.003a 232.5 ± 158.43 0.017a
 III + IV 55 (43.7) 393.47 ± 203.17 310.85 ± 194.09
Child‑pugh classification
 A 51 (40.4) 265.75 ± 209.34 0.006b 203.08 ± 164.94 0.000b
 B 33 (26.3) 400.58 ± 199.30 357.45 ± 149.83
 C 42 (33.3) 355.50 ± 192.4 272.67 ± 186.31
Table 2 CCT3 and IQGAP3 protein level in different patient groups
* P < 0.05 (vs. cirrhosis)
** P < 0.05 (vs. healthy controls
*** P < 0.05 (vs. HCC)
#  P > 0.05 (vs. healthy controls)
Groups Patients (n) CCT3 mean ± SD, pg/mL P value IQGAP3 mean ± SD, pg/mL P value
Total HCC 126 330.98 ± 207.51 <0.01* 266.71 ± 178.47 <0.01*
Cirrhosis 88 82.03 ± 96.53 <0.05** 66.44 ± 63.97 >0.05#
Healthy controls 50 50.34 ± 27.27 <0.01*** 59.50 ± 51.08 <0.01***
AFP‑negative HCC 38 337.66 ± 202.55 <0.01* 261.05 ± 171.20 <0.01*
Small HCC 47 279.13 ± 217.02 <0.01* 212.74 ± 170.73 <0.01*
AFP‑negative small HCC 27 306.56 ± 1196.48 <0.01* 232.41 ± 149.13 <0.01*
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used to compare the distribution of CCT3 and IQGAP3 
levels and clinical variables among HCC groups. All P val-
ues were derived from two-sided tests, and P < 0.05 was 
considered statistically significant. Correlation between 
CCT3 and IQGAP3 levels was assessed using Spearman 
correlation test. To compare abilities of tumor mark-
ers in diagnosis of HCC, receiver operator characteristic 
(ROC) curves, which correlate true- and false-positive 
rates [sensitivity and (1 − specificity)], were constructed 
using the RocKIT (University of Chicago,USA). A logis-
tic regression model was used to analyze sensitivity and 
specificity of biomarkers. Additionally, areas under the 
ROC curve (AUC) were calculated for each marker. The 
statistical significance of differences between the two 
AUCs was determined. The optimal cutoff values were 
calculated using the maximum sum of sensitivity and 
specificity. Statistical analysis was conducted using SPSS 
for Windows version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Clinicopathological features of serum CCT3 and IQGAP3 
expression in HCC patients
Clinical characteristics of all 126 HCC patients (84 
male and 42 female) were shown in Table  1: 57.1  % 
had HBV-related hepatitis; 24.6  % had HCV-related 
hepatitis; 37.3  % had small tumors (single nodule and 
diameter  ≤2  cm); and 30.1  % had AFP-negative HCC 
(<20.0 ng/mL). The patients in HCC group, 56.3 % were 
staged as TNM I + II and 43.7 % as III + IV; 40.4 % of 
patients were classified as child-pugh A, 26.3 % as child-
pugh B and 33.3  % as child-pugh C. We found that 
CCT3 and IQGAP3 protein levels were correlated with 
etiology of HCC, tumor size, number of cancer nod-
ules and child-pugh classification (P  <  0.05). Further-
more, (Fig.  1) also indicated that there was correlation 
between plasma CCT3 and IQGAP3 levels (r =  0.824, 
P < 0.01).
Serum CCT3 and IQGAP3 level in patients with liver 
diseases and healthy controls
To investigate concentration of serum CCT3 and 
IQGAP3 in patients with different liver diseases and 
healthy persons, the levels of CCT3 and IQGAP3 in 
peripheral blood were detected by ELISA. Expression of 
serum CCT3 in patients with HCC (330.98 ± 207.51 pg/
mL) was significantly higher (P < 0.001) than in patients 
with cirrhosis (82.03  ±  96.53  pg/mL), or healthy con-
trols (50.34  ±  27.27  pg/mL) (Table  2). Similarly, 
expression of serum IQGAP3 in patients with HCC 
(266.71 ± 178.47 pg/mL) was evidently higher (P < 0.001) 
than that in patients with cirrhosis (66.44  ±  63.97  pg/
mL), or healthy controls (59.50 ± 51.08 pg/mL).
Plasma CCT3 and IQGAP3 protein levels in patients 
with small and AFP‑negative tumors
We compared the levels of CCT3 and IQGAP3 protein in 
patients with small (n = 47) and AFP-negative (n = 38) 
tumors. In the small HCC group, the CCT3 AUC was 
0.761, with 95  % Confidence interval (CI) 0.663–0.860, 
and IQGAP3 AUC was 0.753 (95  % CI 0.651–0.855). 
AFP AUC was 0.707 (95  % CI 0.604–0.811). CCT3 
and IQGAP3 had a larger AUC than AFP had (Fig.  2a, 
P < 0.01). When the cut-off value for CCT3 was selected 
at 46.5  pg/mL, as determined by maximum sensitivity 
and specificity, the sensitivity and specificity for CCT3 
were 76.6 and 70.5  %, respectively. When the cut-off 
value for IQGAP3 was selected at 43.5  pg/mL, the sen-
sitivity and specificity for IQGAP3 were 74.5 and 71.6 %, 
respectively, while the sensitivity and specificity for AFP 
(20  ng/mL), were 53.2 and 68.2  %, respectively. Thus, 
CCT3 and IQGAP3 showed superiority to AFP in detect-
ing small HCC tumors.
In addition, plasma CCT3 and IQGAP3 from 38 AFP-
negative HCC and 88 cirrhosis patients were analyzed. 
Their AFP levels were  <20  ng/mL. AUC for CCT3 was 
0.871 (95 % CI 0.791–0.951, Fig. 2b, P < 0.01). When the 
cut-off value for CCT3 was selected at 46.5  pg/mL, the 
sensitivity was 92.1  % and specificity was 70.5  %. AUC 
for IQGAP3 was 0.804 (95  % CI 0.694–0.914, Fig.  2b, 
P  <  0.01). When the cut-off value for IQGAP3 was 
selected at 43.5  pg/mL, the sensitivity was 81.6  % and 
specificity was 71.6 %.
Furthermore, among 47 patients with small HCC, 27 
were negative for AFP. Their AUC for CCT3 was 0.84 
(95  % CI 0.735–0.945, Fig.  2c, P  <  0.01) when differen-
tiating from cirrhosis; its sensitivity and specificity were 
88.9 and 70.5 %, respectively, when the cut-off value was 
selected at 46.5  pg/mL. AUC for IQGAP3 was 0.822 
(95 % CI 0.700–0.943, Fig. 2c, P < 0.01); when differen-
tiating from cirrhosis, its sensitivity and specificity were 
85.2 and 71.6 %, respectively, when the cut-off value was 
selected at 43.5 pg/mL.
Combined diagnostic value of plasma CCT3, IQGAP3 
and AFP
AUC was calculated to compare the accuracy achieved 
when using AFP, CCT3 and IQGAP3 for diagnosis of 
HCC (Fig.  2d). AUC for AFP (0.815, 95  % CI 0.758–
0.872) and CCT3 (0.846, 95  % CI 0.791–0.901) was 
higher than for IQGAP3 (0.808, 95  % CI 0.747–0.869). 
High levels of plasma CCT3 protein were detected in 
HCC, and CCT3 had higher sensitivity (87.3  %) than 
AFP (69.8  %) in differentiating HCC from cirrhosis 
when the cut-off value was selected at 46.5  pg/mL and 
20  ng/mL, respectively (P  <  0.05). We also analyzed the 
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complementary properties of using CCT3 and IQGAP3 
in combination with AFP for the diagnosis of HCC, using 
a logistic regression model,with “0” represents the cir-
rhosis group, “1” represents liver cancer. Obtain the fol-
lowing regression equation: P =  1/[1 +  e−(−3.413+0.007X1+
0.020X2+0.007X3)], X1, X2 and X3 respectively represents 
AFP, CCT3 and IQGAP3, values of OR were: 1.008, 1.020 
and 1.007, respectively. 95  % Confidence intervals were 
(1.007–1.012), (1.010–1.031), (1.001–1.012), respectively 
(Table  3). Thus, CCT3, IQGAP3 and AFP are the inde-
pendent factors of HCC. High risk of HCC in patients 
with high expression of CCT3 is 1.200 times that of lower 
levels, AFP is 1.008 times and IQGAP3 is 1.007 times, 
respectively. Thus, the expression of CCT3 and IQGAP3 
are independent of AFP.
The combined use of AFP, CCT3 and IQGAP3 fur-
ther increased the AUC (0.954; 95  % CI 0.925–0.982), 
which was higher than that just using AFP alone (Fig. 2e 
P < 0.01).
Discussion
HCC is one of the most severe types of cancer. It has a 
high incidence and is the third most common cause of 
cancer mortality, with 696,000 cases worldwide each year 
[20–22]. The mortality is partly due to unresponsiveness 
to treatment, and the 5-year survival rate was <5 % after 
diagnosis [23]. AFP is a commonly used tumor marker 
for the early screening of primary HCC. However, AFP as 
a sole indicator of HCC is of limited value. Statistical data 
confirmed that the diagnostic sensitivity of AFP for small 
HCC tumors is only 20–40 %. Nearly one-third of early 
stage, small HCC tumors (<2  cm) cannot be detected 
using AFP screening [24, 25]. In contrast, the level of 
serum AFP does not reflect the severity of the patient’s 
condition, nor effectively assess HCC prognosis.
Eukaryotic CCT3 consists of two identical rings, each 
with eight different CCT subunits. Through a variety of 
structural, functional and cell biology methods, interac-
tions between TRiC and its main substrates, actin and 
Fig. 1 Correlation plasma CCT3 levels with IQGAP3 levels. The correlation of CCT3 level with IQGAP3 level was analyzed in 126 HCC patients. Points 
show CCT3 or IQGAP3 levels of each of participants, with X axle indicates IQGAP3 levels (pg/mL), and Y axle indicates CCT3 levels (pg/mL)
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tubulin, have been well characterized [26, 27]. The chap-
eronins are key molecular complexes that are essential 
in protein folding to produce stable and functionally 
competent protein conformations [28, 29]. In this study, 
high levels of plasma CCT3 protein were detected in 
HCC, and CCT3 had better sensitivity (87.3 %) than AFP 
(69.8  %) in differentiating HCC from cirrhosis. Further-
more, the AUC for CCT3 (0.865) was larger than that of 
AFP (0.815), which is consistent with Yokota et  al. [30] 
who reported increased expression of cytosolic chaper-
onin CCT in human HCC and colonic carcinoma. Sig-
nificant overexpression of CCT3 in HCC has also been 
reported by Wong et al. [12].
IQGAPs is a newly discovered protein family and its 
sequence displays extensive sequence similar to the cata-
lytic domain of RasGAPS, and four IQ motifs located in 
the N-terminal which can interact with calmodulin, and 
in mammals there are three homologous IQGAPs 1–3. 
IQGAP3 is located at 1q22, which is a hotspot for gene 
amplification in cancer and expressed in liver and intes-
tines and other organs restrictively [31]. DNA amplifica-
tion at 1q22 is linked with gastroesophageal carcinoma 
and infiltrating ductal carcinoma of the breast [32, 
33]. In this study, we observed higher levels of serum 
IQGAP3 in patients with HCC than in patients without 
Fig. 2 ROC curve of CCT3,IQGAP3 and AFP in HCC, cirrhosis patients. ROC curve were used to analyze the diagnostic performance of CCT3 and 
IQGAP3 from different groups. The area under the ROC curve (AUC) was shown with 95 % Confidence intervals. a ROC curve of CCT3 and IQGAP3 
in differentiating small HCC from cirrhosis patients. b ROC curve of CCT3 and IQGAP3 in differentiating AFP‑negative HCC from cirrhosis patients. c 
ROC curve of CCT3 and IQGAP3 in differentiating AFP‑negative small HCC from cirrhosis patients. d ROC curve of comparing the accuracy achieved 
when using AFP, CCT3 and IQGAP3 for diagnosis of HCC. e ROC curve of AFP and combined use of AFP, CCT3 and IQGAP3
Table 3 Logistic regression analysis
Factor Regression coefficient P OR 95 % CI
AFP 0.007 0.001 1.008 1.007–1.012
CCT3 0.020 0.000 1.020 1.010–1.031
IQGAP3 0.007 0.000 1.007 1.001–1.012
Constant −3.413 0.000 0.033
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HCC. Skawran et  al. [13] demonstrated that CCT3 and 
IQGAP3 are upregulated most significantly by gene set 
enrichment analysis in HCC.
In this work, we found that concentration of serum 
CCT3 and IQGAP3 in patients with HCC was cor-
related with etiology, tumor size, number of cancer 
nodules and child-pugh classification, indicating that 
they are novel predictors for HCC. Yuan et al. reported 
that CCT3 has the potential as a new tumor marker 
for early detection of cholangiocarcinoma [34]. Ying 
et al. demonstrated that IQGAP3 may contribute to the 
pathogenesis of lung cancer by modulating GFR-ERK 
signaling [35].
The prognosis of HCC can be largely improved if 
it is detected at an early stage. However, detection of 
early stage and AFP-negative HCC is still difficult clini-
cally, even with the help of advanced imaging technol-
ogy. Accurate detection of AFP-negative and small 
HCC tumors can lead to early diagnosis, treatment, and 
reduced cancer-related mortality. This study showed that 
CCT3 and IQGAP3 are superior to AFP in predicting 
HCC prognosis. In AFP-negative HCC group, the sen-
sitivity of CCT3 and IQGAP3 was 92.1 and 81.6 % and 
specificity was 70.5, 71.6 %, respectively. We also evalu-
ated whether CCT3 and IQGAP3 could be used as mark-
ers for the detection of small HCC tumors. Our data 
showed that serum CCT3 levels in patients with small 
tumors (≤2  cm) provided a sensitivity of 76.6  % when 
distinguishing small HCC from cirrhosis at a cut-off 
value of 46.5  pg/mL. IQGAP3 had sensitivity of 74.5  % 
when distinguishing small HCC from cirrhosis at a cut-
off value of 43.5 pg/mL. AFP had a sensitivity of 74.5 %. 
In the AFP-negative small HCC group, the sensitivity of 
CCT3 and IQGAP3 was 88.9 and 85.2  %, respectively. 
These results suggest that CCT3 and IQGAP3 can be 
complementary to AFP in the diagnosis of AFP-negative 
and small HCC.
Combination of CCT3, IQGAP3 and AFP could sig-
nificantly increase the sensitivity of each agent for HCC 
diagnosis. However, the specificity is also reduced. 
The combined use of AFP, CCT3 and IQGAP3 further 
increased the AUC (0.954; 95 % CI 0.925–0.982), which 
was higher than that using AFP alone (0.815; 95  %CI 
0.758–0.872).
Conclusions
In summary, our findings indicate that CCT3 and IQGAP3 
are novel biomarkers complementary to AFP in HCC 
diagnosis, whose expression is independent of AFP. This 
is especially valuable when AFP is negative and HCC is at 
an early stage. Thus, CCT3 and IQGAP3 should be use-
ful biomarkers, in combination with AFP, to confirm the 
diagnosis of HCC. Future works are required to explore 
whether CCT3 and IQGAP3 can also predict patients’ sur-
vival and their usefulness in clinical application.
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